Latest Breaking News On - Prnewswire precigen inc - Page 3 : vimarsana.com

Precigen Announces Proposed $75.0 Million Public Offering of Common Stock

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of $75.0 million of its common stock. In...

Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen to Announce Third Quarter 2022 Financial Results on November 9th

Precigen to Announce Third Quarter 2022 Financial Results on November 9th

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen to Announce Third Quarter 2022 Financial Results on November 9th

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference

Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...